New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed...
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor...
MURFREESBORO, TN / ACCESSWIRE / December 2, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that Candice Todd will...
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study...
MURFREESBORO, TN / ACCESSWIRE / November 5, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that after more than...
MURFREESBORO, TN / ACCESSWIRE / November 5, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay...
Eric Hakimov to Lead M&A Strategy and Integration Efforts RESTON, Va., Nov. 4, 2024 /PRNewswire/ -- ICF (NASDAQ:ICFI), a global consulting...
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), a cannabis...
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS...
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline...
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual...
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct....
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of...
Advancing CEPI's 100 Days Mission to Accelerate Vaccine Development DUSSELDORF, Germany, Oct. 2, 2024 /PRNewswire/ -- LenioBio, the leader in rapid...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark...
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for...
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old...